You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTopiramate
Accession NumberDB00273  (APRD00237)
TypeSmall Molecule
GroupsApproved
Description

Topiramate (brand name Topamax) is an anticonvulsant drug produced by Ortho-McNeil Neurologics, a division of Johnson & Johnson. It is used to treat epilepsy in both children and adults. In children it is also indicated for treatment of Lennox-Gastaut syndrome (a disorder that causes seizures and developmental delays). It is also Food and Drug Administration (FDA) approved for, and now most frequently prescribed for, the prevention of migraines. [Wikipedia]. A combination product containing phentermine and topiramate extended-release called QSYMIA® is indicated for the management of obesity. On August 2013, an extended released formulation, marketed as Trokendi XR has been approved for the management of partial onset, tonic-clonic, and Lennox-Gastaut Syndrome seizures.

Structure
Thumb
Synonyms
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate
McN-4853
RWJ-17021
Tipiramate
Tipiramato
Topamax
Topiramate
Topiramato
Topiramatum
TPM
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-topiramatetablet200 mgoralBgp Pharma Ulc2014-03-172015-12-31Canada
Abbott-topiramatetablet100 mgoralBgp Pharma Ulc2014-03-122015-12-31Canada
Abbott-topiramatetablet25 mgoralBgp Pharma Ulc2014-03-122015-12-31Canada
Accel-topiramatetablet200 mgoralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-topiramatetablet100 mgoralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-topiramatetablet25 mgoralAccel Pharma Inc2015-03-26Not applicableCanada
Act Topiramatetablet200 mgoralActavis Pharma Company2007-07-12Not applicableCanada
Act Topiramatetablet100 mgoralActavis Pharma Company2007-07-12Not applicableCanada
Act Topiramatetablet25 mgoralActavis Pharma Company2007-07-12Not applicableCanada
Auro-topiramatetablet200 mgoralAurobindo Pharma Limited (Unit Iii)2011-11-28Not applicableCanada
Auro-topiramatetablet50 mgoralAurobindo Pharma Limited (Unit Iii)Not applicableNot applicableCanada
Auro-topiramatetablet100 mgoralAurobindo Pharma Limited (Unit Iii)2011-11-28Not applicableCanada
Auro-topiramatetablet25 mgoralAurobindo Pharma Limited (Unit Iii)2011-11-28Not applicableCanada
Ava-topiramatetablet200 mgoralAvanstra Inc2011-10-112014-08-21Canada
Ava-topiramatetablet100 mgoralAvanstra Inc2011-10-112014-08-21Canada
Ava-topiramatetablet25 mgoralAvanstra Inc2011-10-112014-08-21Canada
Dom-topiramatetablet200 mgoralDominion Pharmacal2005-09-29Not applicableCanada
Dom-topiramatetablet100 mgoralDominion Pharmacal2005-09-29Not applicableCanada
Dom-topiramatetablet25 mgoralDominion Pharmacal2005-09-29Not applicableCanada
Gd-topiramatetablet200 mgoralGenmed A Division Of Pfizer Canada Inc2012-05-102015-08-25Canada
Gd-topiramatetablet100 mgoralGenmed A Division Of Pfizer Canada Inc2012-05-102014-12-10Canada
Gd-topiramatetablet25 mgoralGenmed A Division Of Pfizer Canada Inc2012-05-102014-12-10Canada
Ipg-topiramatetablet200 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-topiramatetablet100 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-topiramatetablet25 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-topiramatetablet200 mgoralJamp Pharma Corporation2015-02-06Not applicableCanada
Jamp-topiramatetablet100 mgoralJamp Pharma Corporation2015-02-06Not applicableCanada
Jamp-topiramatetablet25 mgoralJamp Pharma Corporation2015-02-06Not applicableCanada
Mar-topiramatetablet100 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-topiramatetablet25 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-topiramatetablet200 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mint-topiramatetablet100 mgoralMint Pharmaceuticals Inc2008-10-01Not applicableCanada
Mint-topiramatetablet25 mgoralMint Pharmaceuticals Inc2008-10-02Not applicableCanada
Mint-topiramatetablet200 mgoralMint Pharmaceuticals Inc2008-10-01Not applicableCanada
Mylan-topiramatetablet100 mgoralMylan Pharmaceuticals Ulc2005-09-14Not applicableCanada
Mylan-topiramatetablet25 mgoralMylan Pharmaceuticals Ulc2005-09-14Not applicableCanada
Mylan-topiramatetablet200 mgoralMylan Pharmaceuticals Ulc2005-09-14Not applicableCanada
Nu-topiramatetablet200 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-topiramatetablet100 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-topiramatetablet50 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-topiramatetablet25 mgoralNu Pharm IncNot applicableNot applicableCanada
PHL-topiramatetablet200 mgoralPharmel Inc2005-10-11Not applicableCanada
PHL-topiramatetablet100 mgoralPharmel Inc2005-10-11Not applicableCanada
PHL-topiramatetablet25 mgoralPharmel Inc2005-10-11Not applicableCanada
PMS-topiramatetablet200 mgoralPharmascience Inc2005-09-14Not applicableCanada
PMS-topiramatetablet50 mgoralPharmascience Inc2008-06-17Not applicableCanada
PMS-topiramatetablet100 mgoralPharmascience Inc2005-09-14Not applicableCanada
PMS-topiramatetablet25 mgoralPharmascience Inc2005-09-14Not applicableCanada
Pro-topiramatetablet200 mgoralPro Doc Limitee2008-10-27Not applicableCanada
Pro-topiramatetablet100 mgoralPro Doc Limitee2008-10-27Not applicableCanada
Pro-topiramatetablet25 mgoralPro Doc Limitee2008-10-27Not applicableCanada
Q-topiramatetablet100 mgoralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Q-topiramatetablet200 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-topiramatetablet25 mgoralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Qudexy XRcapsule, extended release25 mg/1oralUpsher Smith Laboratories, Inc.2014-04-11Not applicableUs
Qudexy XRcapsule, extended release150 mg/1oralUpsher Smith Laboratories, Inc.2014-04-11Not applicableUs
Qudexy XRcapsule, extended release100 mg/1oralUpsher Smith Laboratories, Inc.2014-04-11Not applicableUs
Qudexy XRcapsule, extended release200 mg/1oralUpsher Smith Laboratories, Inc.2014-04-11Not applicableUs
Qudexy XRcapsule, extended release50 mg/1oralUpsher Smith Laboratories, Inc.2014-04-11Not applicableUs
Ran-topiramatetablet200 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-03-22Not applicableCanada
Ran-topiramatetablet100 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-03-22Not applicableCanada
Ran-topiramatetablet25 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-03-22Not applicableCanada
Ratio-topiramatetablet200 mgoralTeva Canada Limited2005-09-142012-07-21Canada
Ratio-topiramatetablet100 mgoralTeva Canada Limited2005-09-142012-07-21Canada
Ratio-topiramatetablet25 mgoralTeva Canada Limited2005-09-142012-07-21Canada
Sandoz Topiramatetablet200 mgoralSandoz Canada Incorporated2005-09-14Not applicableCanada
Sandoz Topiramatetablet100 mgoralSandoz Canada Incorporated2005-09-14Not applicableCanada
Sandoz Topiramatetablet25 mgoralSandoz Canada Incorporated2005-09-14Not applicableCanada
Sandoz Topiramate Tabletstablet100 mgoralSandoz Canada Incorporated2014-10-31Not applicableCanada
Sandoz Topiramate Tabletstablet200 mgoralSandoz Canada Incorporated2014-10-31Not applicableCanada
Sandoz Topiramate Tabletstablet25 mgoralSandoz Canada Incorporated2014-10-31Not applicableCanada
Teva-topiramatetablet200 mgoralTeva Canada Limited2005-11-25Not applicableCanada
Teva-topiramatetablet100 mgoralTeva Canada Limited2005-09-14Not applicableCanada
Teva-topiramatetablet25 mgoralTeva Canada Limited2005-09-14Not applicableCanada
Topamaxtablet, coated25 mg/1oralbryant ranch prepack1997-01-01Not applicableUs
Topamaxtablet, coated50 mg/1oralRebel Distributors Corp1997-01-01Not applicableUs
Topamaxcapsule, coated pellets25 mg/1oralJanssen Pharmaceuticals, Inc.1998-11-01Not applicableUs
Topamaxtablet, coated50 mg/1oralPd Rx Pharmaceuticals, Inc.1997-01-01Not applicableUs
Topamaxtablet, coated200 mg/1oralJanssen Pharmaceuticals, Inc.1997-01-01Not applicableUs
Topamaxtablet, coated50 mg/1oralPhysicians Total Care, Inc.2005-07-05Not applicableUs
Topamaxtablet, coated100 mg/1oralJanssen Pharmaceuticals, Inc.1997-01-01Not applicableUs
Topamaxtablet, coated200 mg/1oralPhysicians Total Care, Inc.2004-11-29Not applicableUs
Topamaxcapsule25 mgoralJanssen Inc1999-06-11Not applicableCanada
Topamaxtablet, coated50 mg/1oralJanssen Pharmaceuticals, Inc.1997-01-01Not applicableUs
Topamaxtablet, coated100 mg/1oralPhysicians Total Care, Inc.2003-07-23Not applicableUs
Topamaxcapsule15 mgoralJanssen Inc1999-06-11Not applicableCanada
Topamaxtablet, coated25 mg/1oralJanssen Pharmaceuticals, Inc.1997-01-01Not applicableUs
Topamaxtablet, coated25 mg/1oralPhysicians Total Care, Inc.2004-01-08Not applicableUs
Topamaxtablet, coated25 mg/1oralRebel Distributors Corp1997-01-01Not applicableUs
Topamaxtablet, coated100 mg/1oralRebel Distributors Corp1997-01-01Not applicableUs
Topamaxcapsule, coated pellets15 mg/1oralJanssen Pharmaceuticals, Inc.1998-11-01Not applicableUs
Topamax 100mgtablet100 mgoralJanssen Inc1997-03-25Not applicableCanada
Topamax 200mgtablet200 mgoralJanssen Inc1997-03-25Not applicableCanada
Topamax 25mgtablet25 mgoralJanssen Inc1997-03-25Not applicableCanada
Topiramatetablet25 mgoralMeliapharm Inc2010-06-112014-06-26Canada
Topiramatetablet25 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Topiramatetablet200 mgoralMeliapharm Inc2010-06-112014-06-25Canada
Topiramatetablet200 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Topiramatetablet25 mgoralSivem Pharmaceuticals Ulc2012-07-20Not applicableCanada
Topiramatecapsule, extended release50 mg/1oralUpsher Smith Laboratories, Inc.2014-07-07Not applicableUs
Topiramatetablet100 mgoralSanis Health Inc2010-10-06Not applicableCanada
Topiramatecapsule, extended release25 mg/1oralUpsher Smith Laboratories, Inc.2014-07-07Not applicableUs
Topiramatetablet25 mgoralSanis Health Inc2010-10-06Not applicableCanada
Topiramatetablet200 mgoralSivem Pharmaceuticals UlcNot applicableNot applicableCanada
Topiramatecapsule, extended release150 mg/1oralUpsher Smith Laboratories, Inc.2014-07-07Not applicableUs
Topiramatetablet50 mgoralSivem Pharmaceuticals UlcNot applicableNot applicableCanada
Topiramatecapsule, extended release100 mg/1oralUpsher Smith Laboratories, Inc.2014-07-07Not applicableUs
Topiramatetablet100 mgoralMeliapharm Inc2010-06-112014-06-25Canada
Topiramatetablet100 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Topiramatetablet100 mgoralSivem Pharmaceuticals Ulc2012-07-20Not applicableCanada
Topiramatecapsule, extended release200 mg/1oralUpsher Smith Laboratories, Inc.2014-07-07Not applicableUs
Topiramatetablet200 mgoralSanis Health Inc2010-10-06Not applicableCanada
Topiramate Tabletstablet200 mgoralAccord Healthcare Inc2012-11-29Not applicableCanada
Topiramate Tabletstablet200 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Topiramate Tabletstablet100 mgoralAccord Healthcare Inc2012-12-14Not applicableCanada
Topiramate Tabletstablet100 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Topiramate Tabletstablet25 mgoralAccord Healthcare Inc2012-11-29Not applicableCanada
Topiramate Tabletstablet25 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Topiramate Tablets USPtablet100 mgoralAccord Healthcare Inc2014-11-14Not applicableCanada
Topiramate Tablets USPtablet25 mgoralAccord Healthcare Inc2014-11-14Not applicableCanada
Topiramate Tablets USPtablet200 mgoralAccord Healthcare Inc2014-11-14Not applicableCanada
Trokendi XRcapsule, extended release200 mg/1oralSupernus Pharmaceuticals, Inc.2013-08-16Not applicableUs
Trokendi XRcapsule, extended release100 mg/1oralSupernus Pharmaceuticals, Inc.2013-08-16Not applicableUs
Trokendi XRcapsule, extended release50 mg/1oralSupernus Pharmaceuticals, Inc.2013-08-16Not applicableUs
Trokendi XRcapsule, extended release25 mg/1oralSupernus Pharmaceuticals, Inc.2013-08-16Not applicableUs
Van-topiramatetablet200 mgoralVanc Pharmaceuticals IncNot applicableNot applicableCanada
Van-topiramatetablet100 mgoralVanc Pharmaceuticals IncNot applicableNot applicableCanada
Van-topiramatetablet25 mgoralVanc Pharmaceuticals IncNot applicableNot applicableCanada
Zym-topiramatetablet200 mgoralZymcan Pharmaceuticals Inc2009-06-232014-06-16Canada
Zym-topiramatetablet100 mgoralZymcan Pharmaceuticals Inc2009-06-232014-06-16Canada
Zym-topiramatetablet25 mgoralZymcan Pharmaceuticals Inc2009-06-232014-06-16Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-topiramatetablet100 mgoralApotex Inc2006-04-21Not applicableCanada
Apo-topiramatetablet25 mgoralApotex Inc2006-04-21Not applicableCanada
Apo-topiramatetablet50 mgoralApotex IncNot applicableNot applicableCanada
Apo-topiramatetablet200 mgoralApotex Inc2006-04-21Not applicableCanada
Topiramatetablet, film coated100 mg/1oralPhysicians Total Care, Inc2009-05-08Not applicableUs
Topiramatetablet25 mg/1oralGolden State Medical Supply, Inc.2009-03-27Not applicableUs
Topiramatetablet25 mg/1oralSt Marys Medical Park Pharmacy2010-12-29Not applicableUs
Topiramatetablet, film coated50 mg/1oralProficient Rx LP2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralTYA Pharmaceuticals2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralDispensing Solutions Inc.2009-04-13Not applicableUs
Topiramatetablet, film coated50 mg/1oralPreferred Pharmacetucals, Inc.2013-12-18Not applicableUs
Topiramatetablet, film coated25 mg/1oralREMEDYREPACK INC.2016-02-09Not applicableUs
Topiramatetablet, film coated25 mg/1oralRebel Distributors Corp2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralMajor Pharmaceuticals2009-06-10Not applicableUs
Topiramatetablet, coated200 mg/1oralUpsher Smith Laboratories, Inc.2011-05-02Not applicableUs
Topiramatetablet, film coated25 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-29Not applicableUs
Topiramatetablet, film coated50 mg/1oralPd Rx Pharmaceuticals, Inc.2009-03-27Not applicableUs
Topiramatetablet50 mg/1oralREMEDYREPACK INC.2012-03-12Not applicableUs
Topiramatetablet, film coated100 mg/1oralNorthwind Pharmaceuticals, LLC2015-02-02Not applicableUs
Topiramatetablet, film coated100 mg/1oralRebel Distributors Corp2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-28Not applicableUs
Topiramatetablet, film coated50 mg/1oralSun Pharma Global FZE2014-12-15Not applicableUs
Topiramatetablet200 mg/1oralREMEDYREPACK INC.2013-02-20Not applicableUs
Topiramatetablet200 mg/1oralREMEDYREPACK INC.2013-04-012016-04-05Us
Topiramatetablet, film coated25 mg/1oralPhysicians Total Care, Inc2009-04-13Not applicableUs
Topiramatetablet100 mg/1oralGolden State Medical Supply, Inc.2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralREMEDYREPACK INC.2015-05-18Not applicableUs
Topiramatetablet, film coated25 mg/1oralProficient Rx LP2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralCadila Healthcare Limited2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralDispensing Solutions Inc.2009-04-13Not applicableUs
Topiramatetablet25 meq/1oralCipla USA Inc.2014-06-12Not applicableUs
Topiramatetablet, film coated100 mg/1oralREMEDYREPACK INC.2016-03-11Not applicableUs
Topiramatetablet25 mg/1oralBlenheim Pharmacal, Inc.2014-01-22Not applicableUs
Topiramatetablet, film coated50 mg/1oralMylan Pharmaceuticals Inc.2012-12-12Not applicableUs
Topiramatetablet25 mg/1oralTeva Pharmaceuticals USA Inc2009-03-31Not applicableUs
Topiramatetablet, film coated100 mg/1oralREMEDYREPACK INC.2014-04-21Not applicableUs
Topiramatetablet, film coated50 mg/1oralClinical Solutions Wholesale2009-03-27Not applicableUs
Topiramatecapsule, coated pellets25 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Topiramatetablet, film coated200 mg/1oralDIRECT RX2015-01-01Not applicableUs
Topiramatetablet, film coated25 mg/1oralRanbaxy Pharmaceuticals Inc2010-01-04Not applicableUs
Topiramatetablet, film coated25 mg/1oralAurobindo Pharma Limited2009-03-27Not applicableUs
Topiramatetablet200 mg/1oralKeltman Pharmaceuticals Inc.2010-07-30Not applicableUs
Topiramatetablet, film coated100 mg/1oralZydus Pharmaceuticals (USA) Inc.2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralTorrent Pharmaceuticals Limited2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralWest ward Pharmaceutical Corp2013-12-02Not applicableUs
Topiramatetablet25 mg/1oralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs
Topiramatetablet, film coated50 mg/1oralPd Rx Pharmaceuticals, Inc.2009-03-27Not applicableUs
Topiramatetablet25 mg/1oralREMEDYREPACK INC.2011-08-22Not applicableUs
Topiramatetablet50 mg/1oralUnit Dose Services2011-01-01Not applicableUs
Topiramatetablet, coated100 mg/1oralUpsher Smith Laboratories, Inc.2011-05-02Not applicableUs
Topiramatetablet100 mg/1oralAidarex Pharmaceuticals LLC2011-01-01Not applicableUs
Topiramatetablet, film coated100 mg/1oralPd Rx Pharmaceuticals, Inc.2009-03-27Not applicableUs
Topiramatetablet200 mg/1oralREMEDYREPACK INC.2011-11-17Not applicableUs
Topiramatetablet, film coated25 mg/1oralNorthwind Pharmaceuticals, LLC2015-02-10Not applicableUs
Topiramatetablet, film coated25 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Topiramatetablet, film coated200 mg/1oralHikma Pharmaceutical2013-12-02Not applicableUs
Topiramatetablet100 mg/1oralSt Marys Medical Park Pharmacy2010-12-24Not applicableUs
Topiramatetablet, film coated200 mg/1oralSun Pharmaceutical Industries Limited2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralbryant ranch prepack2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralAmerican Health Packaging2012-06-01Not applicableUs
Topiramatetablet, film coated100 mg/1oralPreferred Pharmacetucals, Inc.2013-12-18Not applicableUs
Topiramatetablet, film coated200 mg/1oralCitron Pharma LLC2009-03-27Not applicableUs
Topiramatetablet50 mg/1oralSTAT Rx USA LLC2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralMajor Pharmaceuticals2009-06-10Not applicableUs
Topiramatetablet, film coated25 mg/1oralREMEDYREPACK INC.2014-03-12Not applicableUs
Topiramatetablet, film coated200 mg/1oralClinical Solutions Wholesale2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralApotex Corp2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralDIRECT RX2014-01-01Not applicableUs
Topiramatetablet, film coated50 mg/1oralProficient Rx LP2009-03-27Not applicableUs
Topiramatecapsule, coated pellets25 mg/1oralCadila Healthcare Limited2009-10-14Not applicableUs
Topiramatetablet100 mg/1oralKeltman Pharmaceuticals Inc.2010-07-30Not applicableUs
Topiramatetablet, film coated50 mg/1oralZydus Pharmaceuticals (USA) Inc.2009-03-27Not applicableUs
Topiramatetablet50 mg/1oralTorrent Pharmaceuticals Limited2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-03-27Not applicableUs
Topiramatetablet50 mg/1oralTeva Pharmaceuticals USA Inc2009-03-31Not applicableUs
Topiramatetablet, film coated200 mg/1oralUnichem Pharmaceuticals (USA), Inc.2013-07-01Not applicableUs
Topiramatetablet25 mg/1oralPd Rx Pharmaceuticals, Inc.2009-03-27Not applicableUs
Topiramatetablet50 mg/1oralREMEDYREPACK INC.2011-04-25Not applicableUs
Topiramatetablet25 mg/1oralUnit Dose Services2011-01-01Not applicableUs
Topiramatetablet, coated50 mg/1oralUpsher Smith Laboratories, Inc.2011-05-02Not applicableUs
Topiramatetablet50 mg/1oralAidarex Pharmaceuticals LLC2011-01-01Not applicableUs
Topiramatetablet, film coated25 mg/1oralPd Rx Pharmaceuticals, Inc.2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralREMEDYREPACK INC.2011-11-01Not applicableUs
Topiramatetablet, film coated100 mg/1oralMylan Institutional Inc.2009-04-20Not applicableUs
Topiramatetablet25 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Topiramatetablet, film coated100 mg/1oralHikma Pharmaceutical2013-12-02Not applicableUs
Topiramatetablet50 mg/1oralSt Marys Medical Park Pharmacy2010-12-29Not applicableUs
Topiramatetablet, film coated100 mg/1oralSun Pharmaceutical Industries Limited2009-03-27Not applicableUs
Topiramatetablet50 mg/1oralbryant ranch prepack2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralAmerican Health Packaging2012-06-01Not applicableUs
Topiramatetablet, film coated25 mg/1oralPreferred Pharmaceuticals, Inc.2014-03-14Not applicableUs
Topiramatetablet, film coated100 mg/1oralCitron Pharma LLC2009-03-27Not applicableUs
Topiramatetablet25 mg/1oralSTAT Rx USA LLC2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralMajor Pharmaceuticals2009-06-10Not applicableUs
Topiramatecapsule, coated pellets25 mg/1oralTeva Pharmaceuticals USA Inc2009-04-17Not applicableUs
Topiramatetablet, film coated100 mg/1oralUnichem Pharmaceuticals (USA), Inc.2013-07-01Not applicableUs
Topiramatetablet, film coated100 mg/1oralSTAT Rx USA LLC2009-03-27Not applicableUs
Topiramatetablet25 mg/1oralREMEDYREPACK INC.2013-04-10Not applicableUs
Topiramatetablet200 mg/1oralAv Pak2014-09-17Not applicableUs
Topiramatetablet, film coated50 mg/1oralREMEDYREPACK INC.2014-02-26Not applicableUs
Topiramatetablet, film coated50 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralApotex Corp2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralDIRECT RX2015-01-01Not applicableUs
Topiramatetablet, film coated100 mg/1oralProficient Rx LP2009-03-27Not applicableUs
Topiramatecapsule, coated pellets15 mg/1oralCadila Healthcare Limited2009-10-14Not applicableUs
Topiramatetablet25 mg/1oralKeltman Pharmaceuticals Inc.2010-07-30Not applicableUs
Topiramatetablet, film coated100 mg/1oralPreferred Pharmaceuticals Inc.2016-01-11Not applicableUs
Topiramatetablet, film coated25 mg/1oralZydus Pharmaceuticals (USA) Inc.2009-03-27Not applicableUs
Topiramatetablet25 mg/1oralTorrent Pharmaceuticals Limited2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralAidarex Pharmaceuticals LLC2009-03-27Not applicableUs
Topiramatetablet50 mg/1oralPd Rx Pharmaceuticals, Inc.2009-03-27Not applicableUs
Topiramatetablet25 mg/1oralREMEDYREPACK INC.2011-09-07Not applicableUs
Topiramatetablet, film coated50 mg/1oralMylan Institutional Inc.2009-04-20Not applicableUs
Topiramatetablet, film coated25 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Topiramatetablet, film coated50 mg/1oralHikma Pharmaceutical2013-12-02Not applicableUs
Topiramatetablet25 mg/1oralSt Marys Medical Park Pharmacy2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralSun Pharmaceutical Industries Limited2009-03-27Not applicableUs
Topiramatetablet25 mg/1oralbryant ranch prepack2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralAmerican Health Packaging2012-06-01Not applicableUs
Topiramatetablet, film coated50 mg/1oralGlenmark Pharmaceuticals Inc., Usa2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralCitron Pharma LLC2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralSTAT Rx USA LLC2009-03-27Not applicableUs
Topiramatetablet, coated200 mg/1oralUpsher Smith Laboratories, Inc.2010-11-17Not applicableUs
Topiramatetablet, coated25 mg/1oralUpsher Smith Laboratories, Inc.2011-05-02Not applicableUs
Topiramatetablet, film coated50 mg/1oralUnichem Pharmaceuticals (USA), Inc.2013-07-01Not applicableUs
Topiramatetablet, film coated50 mg/1oralSTAT Rx USA LLC2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralREMEDYREPACK INC.2013-04-102016-04-05Us
Topiramatetablet100 mg/1oralAv Pak2014-09-17Not applicableUs
Topiramatetablet25 mg/1oralREMEDYREPACK INC.2013-05-222016-04-05Us
Topiramatetablet, film coated25 mg/1oralCardinal Health2012-01-05Not applicableUs
Topiramatetablet, film coated50 mg/1oralApotex Corp2009-03-27Not applicableUs
Topiramatetablet25 mg/1oralDIRECT RX2015-01-01Not applicableUs
Topiramatetablet, film coated25 mg/1oralProficient Rx LP2009-03-272016-02-05Us
Topiramatetablet, film coated200 mg/1oralCadila Healthcare Limited2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralDispensing Solutions, Inc.2009-03-27Not applicableUs
Topiramatetablet200 1/1oralCipla USA Inc.2014-06-12Not applicableUs
Topiramatecapsule, coated pellets25 mg/1oralZydus Pharmaceuticals (USA) Inc.2009-10-14Not applicableUs
Topiramatetablet50 mg/1oralApotheca, Inc2010-05-13Not applicableUs
Topiramatetablet, film coated25 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-03-27Not applicableUs
Topiramatecapsule, coated pellets15 mg/1oralTeva Pharmaceuticals USA Inc2009-04-17Not applicableUs
Topiramatetablet200 mg/1oralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs
Topiramatetablet, film coated100 mg/1oralPd Rx Pharmaceuticals, Inc.2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralREMEDYREPACK INC.2011-09-13Not applicableUs
Topiramatetablet, film coated25 mg/1oralMylan Institutional Inc.2009-04-20Not applicableUs
Topiramatetablet50 mg/1oralH.J. Harkins Company, Inc.2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralHikma Pharmaceutical2013-12-02Not applicableUs
Topiramatetablet, coated100 mg/1oralHangzhou Minsheng Binjiang Pharmaceutical CO., Ltd2013-12-31Not applicableUs
Topiramatetablet, film coated25 mg/1oralSun Pharmaceutical Industries Limited2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralbryant ranch prepack2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralAurobindo Pharma Limited2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralGlenmark Pharmaceuticals Inc., Usa2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralCitron Pharma LLC2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralPreferred Pharmaceuticals Inc.2016-04-14Not applicableUs
Topiramatecapsule, coated pellets25 mg/1oralCobalt Laboratories2009-04-15Not applicableUs
Topiramatetablet, coated100 mg/1oralUpsher Smith Laboratories, Inc.2010-11-17Not applicableUs
Topiramatetablet, film coated25 mg/1oralWest ward Pharmaceutical Corp2013-12-02Not applicableUs
Topiramatetablet, film coated25 mg/1oralUnichem Pharmaceuticals (USA), Inc.2013-07-01Not applicableUs
Topiramatetablet, film coated25 mg/1oralSTAT Rx USA LLC2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralSun Pharma Global FZE2014-12-15Not applicableUs
Topiramatetablet50 mg/1oralAv Pak2014-09-17Not applicableUs
Topiramatetablet, film coated100 mg/1oralREMEDYREPACK INC.2013-03-08Not applicableUs
Topiramatetablet, film coated100 mg/1oralCardinal Health2012-01-05Not applicableUs
Topiramatetablet, film coated25 mg/1oralApotex Corp2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralDIRECT RX2015-01-01Not applicableUs
Topiramatetablet50 mg/1oralProficient Rx LP2011-01-01Not applicableUs
Topiramatetablet, film coated100 mg/1oralCadila Healthcare Limited2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralDispensing Solutions, Inc.2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralCipla USA Inc.2014-06-12Not applicableUs
Topiramatecapsule, coated pellets15 mg/1oralZydus Pharmaceuticals (USA) Inc.2009-10-14Not applicableUs
Topiramatetablet25 mg/1oralApotheca, Inc2010-05-13Not applicableUs
Topiramatetablet, film coated200 mg/1oralMylan Pharmaceuticals Inc.2012-12-12Not applicableUs
Topiramatetablet200 mg/1oralTeva Pharmaceuticals USA Inc2009-03-312016-02-29Us
Topiramatetablet100 mg/1oralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs
Topiramatetablet, film coated25 mg/1oralPd Rx Pharmaceuticals, Inc.2009-03-27Not applicableUs
Topiramatetablet50 mg/1oralREMEDYREPACK INC.2011-07-20Not applicableUs
Topiramatetablet, film coated200 mg/1oralUnit Dose Services2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralH.J. Harkins Company, Inc.2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralClinical Solutions Wholesale2009-03-27Not applicableUs
Topiramatetablet, coated50 mg/1oralHangzhou Minsheng Binjiang Pharmaceutical CO., Ltd2013-12-31Not applicableUs
Topiramatetablet50 mg/1oralDIRECT RX2014-01-01Not applicableUs
Topiramatetablet, film coated200 mg/1oralRanbaxy Pharmaceuticals Inc2010-01-04Not applicableUs
Topiramatetablet, film coated100 mg/1oralAurobindo Pharma Limited2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralGlenmark Pharmaceuticals Inc., Usa2009-03-27Not applicableUs
Topiramatetablet25 mg/1oralPreferred Pharmaceuticals Inc.2016-01-04Not applicableUs
Topiramatecapsule, coated pellets15 mg/1oralCobalt Laboratories2009-04-15Not applicableUs
Topiramatetablet, coated50 mg/1oralUpsher Smith Laboratories, Inc.2010-11-17Not applicableUs
Topiramatetablet, film coated50 mg/1oralWest ward Pharmaceutical Corp2013-12-02Not applicableUs
Topiramatetablet, film coated200 mg/1oralPhysicians Total Care, Inc2010-03-22Not applicableUs
Topiramatetablet50 mg/1oralGolden State Medical Supply, Inc.2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralREMEDYREPACK INC.2015-05-18Not applicableUs
Topiramatetablet, film coated100 mg/1oralProficient Rx LP2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralTYA Pharmaceuticals2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralDispensing Solutions Inc.2009-04-13Not applicableUs
Topiramatetablet25 mg/1oralPreferred Pharmaceuticals, Inc.2012-10-31Not applicableUs
Topiramatetablet, film coated200 mg/1oralREMEDYREPACK INC.2016-03-01Not applicableUs
Topiramatetablet, film coated50 mg/1oralRebel Distributors Corp2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralBlenheim Pharmacal, Inc.2013-10-08Not applicableUs
Topiramatetablet, film coated25 mg/1oralMylan Pharmaceuticals Inc.2012-12-12Not applicableUs
Topiramatetablet, film coated50 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-29Not applicableUs
Topiramatetablet, film coated25 mg/1oralSun Pharma Global FZE2014-12-15Not applicableUs
Topiramatetablet200 mg/1oralREMEDYREPACK INC.2012-03-29Not applicableUs
Topiramatetablet, film coated50 mg/1oralNorthwind Pharmaceuticals, LLC2014-11-06Not applicableUs
Topiramatetablet, film coated200 mg/1oralRebel Distributors Corp2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralSun Pharma Global FZE2014-12-15Not applicableUs
Topiramatetablet25 mg/1oralAv Pak2014-09-17Not applicableUs
Topiramatetablet, film coated25 mg/1oralREMEDYREPACK INC.2013-02-26Not applicableUs
Topiramatetablet, film coated50 mg/1oralPhysicians Total Care, Inc2009-05-06Not applicableUs
Topiramatetablet200 mg/1oralGolden State Medical Supply, Inc.2009-03-27Not applicableUs
Topiramatetablet50 mg/1oralDIRECT RX2014-01-01Not applicableUs
Topiramatetablet, film coated25 mg/1oralProficient Rx LP2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralCadila Healthcare Limited2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralDispensing Solutions Inc.2009-04-13Not applicableUs
Topiramatetablet50 mg/1oralCipla USA Inc.2014-06-12Not applicableUs
Topiramatetablet, film coated50 mg/1oralPreferred Pharmaceuticalc Inc.2009-03-27Not applicableUs
Topiramatetablet, film coated50 mg/1oralBlenheim Pharmacal, Inc.2013-10-08Not applicableUs
Topiramatetablet, film coated100 mg/1oralMylan Pharmaceuticals Inc.2012-12-12Not applicableUs
Topiramatetablet100 mg/1oralTeva Pharmaceuticals USA Inc2009-03-31Not applicableUs
Topiramatetablet25 mg/1oralH.J. Harkins Company, Inc.2009-03-27Not applicableUs
Topiramatetablet, film coated100 mg/1oralClinical Solutions Wholesale2009-03-27Not applicableUs
Topiramatetablet, coated25 mg/1oralHangzhou Minsheng Binjiang Pharmaceutical CO., Ltd2013-12-31Not applicableUs
Topiramatetablet, film coated25 mg/1oralDIRECT RX2014-01-01Not applicableUs
Topiramatetablet, film coated100 mg/1oralRanbaxy Pharmaceuticals Inc2010-01-04Not applicableUs
Topiramatetablet, film coated50 mg/1oralAurobindo Pharma Limited2009-03-27Not applicableUs
Topiramatetablet, film coated25 mg/1oralGlenmark Pharmaceuticals Inc., Usa2009-03-27Not applicableUs
Topiramatetablet, film coated200 mg/1oralZydus Pharmaceuticals (USA) Inc.2009-03-27Not applicableUs
Topiramatetablet200 mg/1oralTorrent Pharmaceuticals Limited2009-03-27Not applicableUs
Topiramatetablet, coated25 mg/1oralUpsher Smith Laboratories, Inc.2010-11-17Not applicableUs
Topiramatetablet, film coated100 mg/1oralWest ward Pharmaceutical Corp2013-12-02Not applicableUs
Topiramatetablet50 mg/1oralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs
Topiramatetablet100 mg/1oralPd Rx Pharmaceuticals, Inc.2009-03-27Not applicableUs
Topiramatetablet100 mg/1oralREMEDYREPACK INC.2011-07-19Not applicableUs
Topiramatetablet100 mg/1oralUnit Dose Services2011-01-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
QsymiaVIVUS, Inc.
SaltsNot Available
Categories
UNII0H73WJJ391
CAS number97240-79-4
WeightAverage: 339.362
Monoisotopic: 339.098787343
Chemical FormulaC12H21NO8S
InChI KeyInChIKey=KJADKKWYZYXHBB-XBWDGYHZSA-N
InChI
InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1
IUPAC Name
[(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.0²,⁶]dodecan-6-yl]methyl sulfamate
SMILES
[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dioxolopyrans. These are compounds containing a dioxolopyran moiety, which consistts of a dioxole ring fused to a pyran ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDioxolopyrans
Sub ClassNot Available
Direct ParentDioxolopyrans
Alternative Parents
Substituents
  • Dioxolopyran
  • Oxane
  • Monosaccharide
  • Organic sulfuric acid or derivatives
  • Meta-dioxolane
  • Oxacycle
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed for the treatment and control of partial seizures and severe tonic-clonic (grand mal) seizures and also for the prevention of migraine headaches. In children it is also used for treatment of Lennox-Gastaut syndrome. Qsymia® is indicated for the treatment and management of obesity.
PharmacodynamicsTopiramate is an anticonvulsant indicated in the treatment of epilepsy and migraine. Topiramate enhances GABA-activated chloride channels. In addition, topiramate inhibits excitatory neurotransmission, through actions on kainate and AMPA receptors. There is evidence that topiramate has a specific effect on GluR5 kainate receptors. It is also an inhibitor of carbonic anhydrase, particular subtypes II and IV, but this action is weak and unlikely to be related to its anticonvulsant actions, but may account for the bad taste and the development of renal stones seen during treatment. Its possible effect as a mood stabilizer seems to occur before anticonvulsant qualities at lower dosages. Topiramate inhibits maximal electroshock and pentylenetetrazol-induced seizures as well as partial and secundarily generalized tonic-clonic seizures in the kindling model, findings predective of a broad spectrum of antiseizure activities clinically.
Mechanism of actionThe precise mechanism of action of topiramate is not known. However, studies have shown that topiramate blocks the action potentials elicited repetitively by a sustained depolarization of the neurons in a time-dependent manner, suggesting a state-dependent sodium channel blocking action. Topiramate also augments the activity of the neurotransmitter gamma-aminobutyrate (GABA) at some subtypes of the GABAA receptor (controls an integral chloride channel), indicating a possible mechanism through potentiation of the activity of GABA. Topiramate also demonstrates antagonism of the AMPA/kainate subtype of the glutamate excitatory amino acid receptor. It also inhibits carbonic anhydrase (particularly isozymes II and IV), but this action is weak and unlikely to be related to its anticonvulsant actions.
Related Articles
AbsorptionRapid with pleak plasma concentrations occurring after 2 hours and a bioavailability of 80%. The pharmacokinetic profile of the extended release formulation is non linear at 25 mg due to binding of topiramate to carbonic anhydrase in red blood cells. The peak plasma concentration was 24 hours after a single 200 mg oral dose of the extended release formulation. It is also bioequivalent to immediate-release tablet that has been administered twice-daily. Fluctuation of topiramate plasma concentrations at steady-state for Trokendi XR™ administered once-daily was approximately 26% and 42% in healthy subjects and in epileptic patients, respectively, compared to approximately 40% and 51%, respectively, for immediate-release topiramate. When topiramate is given to elderly and young adults, the maximum plasma concentration was achieved in 1 to 2 hours.
Volume of distributionNot Available
Protein binding15-41% (over the blood concentration range of 0.5 - 250 mg/mL). The fraction bound decreased as blood concentration increased. Carbamazepine and phenytoin do not alter the binding of immediate-release topiramate. Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%. Immediate-release topiramate does not influence the binding of sodium valproate.
Metabolism

Not extensively metabolized, 70% of the dose is eliminated unchanged in the urine. The other 30% is metabolized hepatically to six metabolites (formed by hydroxylation, hydrolysis, and glucuronidation), none of which constitute more than 5% of an administered dose. There is evidence of renal tubular reabsorption of topiramate.

Route of eliminationTopiramate is not extensively metabolized and is primarily eliminated unchanged in the urine (approximately 70% of an administered dose).
Half life19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.
Clearance
  • Plasma clearance (CL/F) =20-30 mL/min [in humans following oral administration]
    Clearance in adults was not affected by gender or race. Pediatric patients on adjunctive treatment exhibited a higher oral clearance compared to those on monotherapy. This may be because of concomitant administration with enzyme-inducing antiepileptic drugs.
ToxicitySymptoms of overdose include abdominal pain, agitation, blurred vision, convulsions, depression, dizziness, double vision, drowsiness, impaired coordination, impaired mental activity, low blood pressure, reduced consciousness, severe diarrhea, sluggishness, and speech problems.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9955
Blood Brain Barrier+0.9382
Caco-2 permeable-0.6055
P-glycoprotein substrateNon-substrate0.7905
P-glycoprotein inhibitor INon-inhibitor0.5311
P-glycoprotein inhibitor IINon-inhibitor0.9479
Renal organic cation transporterNon-inhibitor0.9131
CYP450 2C9 substrateNon-substrate0.9479
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.542
CYP450 1A2 substrateNon-inhibitor0.6623
CYP450 2C9 inhibitorNon-inhibitor0.7259
CYP450 2D6 inhibitorNon-inhibitor0.8674
CYP450 2C19 inhibitorNon-inhibitor0.6539
CYP450 3A4 inhibitorNon-inhibitor0.8469
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7952
Ames testAMES toxic0.518
CarcinogenicityNon-carcinogens0.5578
BiodegradationNot ready biodegradable0.9803
Rat acute toxicity2.5682 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8882
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
  • Barr laboratories inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • Accord healthcare inc
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Cipla ltd
  • Glenmark generics ltd
  • Invagen pharmaceuticals inc
  • Pliva hrvatska doo
  • Ranbaxy laboratories ltd
  • Roxane laboratories inc
  • Sun pharmaceutical industries ltd
  • Torrent pharmaceuticals ltd
  • Unichem laboratories ltd
  • Upsher smith laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral50 mg
Capsule, extended releaseoral
Capsule, extended releaseoral100 mg/1
Capsule, extended releaseoral150 mg/1
Capsule, extended releaseoral200 mg/1
Capsule, extended releaseoral25 mg/1
Capsule, extended releaseoral50 mg/1
Capsuleoral15 mg
Capsuleoral25 mg
Tabletoral100 mg
Tabletoral200 mg
Tabletoral25 mg
Capsule, coated pelletsoral15 mg/1
Capsule, coated pelletsoral25 mg/1
Tabletoral100 mg/1
Tabletoral200 1/1
Tabletoral200 mg/1
Tabletoral25 mg/1
Tabletoral25 meq/1
Tabletoral50 mg/1
Tablet, coatedoral100 mg/1
Tablet, coatedoral200 mg/1
Tablet, coatedoral25 mg/1
Tablet, coatedoral50 mg/1
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral200 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Prices
Unit descriptionCostUnit
Topiramate 200 mg tablet8.32USD tablet
Topamax 200 mg tablet7.68USD tablet
Topiramate 100 mg tablet7.11USD tablet
Topamax 100 mg tablet6.31USD tablet
Topamax 50 mg tablet5.96USD tablet
Topiramate 50 mg tablet5.21USD tablet
Topiramate 25 mg Sprinkle Capsule3.04USD capsule
Topiramate 25 mg tablet2.61USD tablet
Topiramate 99.7% powder2.59USD g
Topiramate 15 mg Sprinkle Capsule2.52USD capsule
Topamax 25 mg tablet2.46USD tablet
Co Topiramate 200 mg Tablet2.08USD tablet
Mylan-Topiramate 200 mg Tablet2.08USD tablet
Novo-Topiramate 200 mg Tablet2.08USD tablet
Phl-Topiramate 200 mg Tablet2.08USD tablet
Pms-Topiramate 200 mg Tablet2.08USD tablet
Ratio-Topiramate 200 mg Tablet2.08USD tablet
Sandoz Topiramate 200 mg Tablet2.08USD tablet
Topamax Sprinkle 25 mg Capsule1.35USD capsule
Sandoz Topiramate 100 mg Tablet1.31USD tablet
Co Topiramate 100 mg Tablet1.31USD tablet
Mylan-Topiramate 100 mg Tablet1.31USD tablet
Novo-Topiramate 100 mg Tablet1.31USD tablet
Phl-Topiramate 100 mg Tablet1.31USD tablet
Pms-Topiramate 100 mg Tablet1.31USD tablet
Ratio-Topiramate 100 mg Tablet1.31USD tablet
Topamax Sprinkle 15 mg Capsule1.29USD capsule
Pms-Topiramate 50 mg Tablet1.05USD tablet
Co Topiramate 25 mg Tablet0.69USD tablet
Mylan-Topiramate 25 mg Tablet0.69USD tablet
Novo-Topiramate 25 mg Tablet0.69USD tablet
Phl-Topiramate 25 mg Tablet0.69USD tablet
Pms-Topiramate 25 mg Tablet0.69USD tablet
Ratio-Topiramate 25 mg Tablet0.69USD tablet
Sandoz Topiramate 25 mg Tablet0.69USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2322644 No2005-07-262019-03-01Canada
US5998380 Yes1996-04-132016-04-13Us
US6071537 No1997-06-232017-06-23Us
US6503884 Yes1996-04-132016-04-13Us
US7018983 Yes1996-04-132016-04-13Us
US7056890 No2000-06-142020-06-14Us
US7125560 Yes1999-09-012019-09-01Us
US7498311 Yes1996-04-132016-04-13Us
US7553818 No2000-06-142020-06-14Us
US7659256 No2000-06-142020-06-14Us
US7674776 No2000-06-142020-06-14Us
US8298576 No2008-04-042028-04-04Us
US8298580 No2007-11-162027-11-16Us
US8580298 No2009-05-152029-05-15Us
US8580299 No2009-06-142029-06-14Us
US8652527 No2013-03-192033-03-19Us
US8663683 No2007-11-162027-11-16Us
US8877248 No2007-11-162027-11-16Us
US8889190 No2013-03-192033-03-19Us
US8889191 No2007-11-162027-11-16Us
US8895057 No2008-06-092028-06-09Us
US8895058 No2008-06-092028-06-09Us
US8992989 No2007-11-162027-11-16Us
US9011905 No2008-06-092028-06-09Us
US9011906 No2008-06-092028-06-09Us
US9101545 No2013-03-192033-03-19Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility9.8 mg/mLNot Available
logP-0.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility6.8 mg/mLALOGPS
logP1.29ALOGPS
logP0.13ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)11.09ChemAxon
pKa (Strongest Basic)-3.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area115.54 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity72.3 m3·mol-1ChemAxon
Polarizability32.42 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Orn Almarsson, “Topiramate salts and compositions comprising and methods of making and using the same.” U.S. Patent US20040053853, issued March 18, 2004.

US20040053853
General References
  1. Blum D, Meador K, Biton V, Fakhoury T, Shneker B, Chung S, Mills K, Hammer A, Isojarvi J: Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology. 2006 Aug 8;67(3):400-6. [PubMed:16894098 ]
External Links
ATC CodesN03AX11
AHFS Codes
  • 28:12.92
PDB EntriesNot Available
FDA labelDownload (236 KB)
MSDSDownload (57.1 KB)
Interactions
Drug Interactions
Drug
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Topiramate.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Topiramate.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Topiramate.
AmitriptylineTopiramate may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Topiramate.
AmphetamineTopiramate may decrease the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Topiramate.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Topiramate.
AzelastineTopiramate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Topiramate.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Topiramate.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Topiramate.
BumetanideBumetanide may increase the hypokalemic activities of Topiramate.
BuprenorphineTopiramate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
CarbamazepineThe serum concentration of Topiramate can be decreased when it is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Topiramate.
CathinoneTopiramate may decrease the excretion rate of Cathinone which could result in a lower serum level and potentially a reduction in efficacy.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Topiramate.
ChlorothiazideChlorothiazide may increase the hypokalemic activities of Topiramate.
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Topiramate.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Topiramate.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Topiramate.
ChlorthalidoneChlorthalidone may increase the hypokalemic activities of Topiramate.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Topiramate.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Topiramate.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Topiramate.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Topiramate.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Topiramate.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Topiramate.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Topiramate.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Topiramate.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Topiramate.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Topiramate.
Dexchlorpheniramine maleateThe risk or severity of adverse effects can be increased when Dexchlorpheniramine maleate is combined with Topiramate.
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Topiramate.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Topiramate.
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Topiramate.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Topiramate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Topiramate.
DisopyramideThe risk or severity of adverse effects can be increased when Disopyramide is combined with Topiramate.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Topiramate.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
Etacrynic acidEthacrynic acid may increase the hypokalemic activities of Topiramate.
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
EthoxzolamideThe risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Topiramate.
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Topiramate.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Topiramate.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Topiramate.
FlavoxateThe risk or severity of adverse effects can be increased when Flavoxate is combined with Topiramate.
FlecainideThe serum concentration of Flecainide can be increased when it is combined with Topiramate.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Topiramate.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Topiramate.
FosphenytoinThe serum concentration of Topiramate can be decreased when it is combined with Fosphenytoin.
FurosemideFurosemide may increase the hypokalemic activities of Topiramate.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrrolate is combined with Topiramate.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Topiramate.
HexamethylenetetramineThe therapeutic efficacy of Hexamethylenetetramine can be decreased when used in combination with Topiramate.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Topiramate.
HydrochlorothiazideHydrochlorothiazide may increase the hypokalemic activities of Topiramate.
HydrocodoneTopiramate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Topiramate.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Topiramate.
IndapamideIndapamide may increase the hypokalemic activities of Topiramate.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Topiramate.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Topiramate.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Topiramate.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Topiramate.
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Topiramate.
LithiumThe serum concentration of Lithium can be increased when it is combined with Topiramate.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Topiramate.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Topiramate.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Topiramate.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Topiramate.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Topiramate.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone Acetate can be decreased when it is combined with Topiramate.
MefloquineThe therapeutic efficacy of Topiramate can be decreased when used in combination with Mefloquine.
MemantineTopiramate may decrease the excretion rate of Memantine which could result in a lower serum level and potentially a reduction in efficacy.
MepenzolateThe risk or severity of adverse effects can be increased when Mepenzolate is combined with Topiramate.
MetforminThe risk or severity of adverse effects can be increased when Topiramate is combined with Metformin.
MethotrimeprazineTopiramate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethscopolamineThe risk or severity of adverse effects can be increased when Methscopolamine is combined with Topiramate.
MethyclothiazideMethyclothiazide may increase the hypokalemic activities of Topiramate.
MetolazoneMetolazone may increase the hypokalemic activities of Topiramate.
MetyrosineTopiramate may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Topiramate can be decreased when used in combination with Mianserin.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
MirtazapineTopiramate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Topiramate.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Topiramate.
NorethisteroneThe serum concentration of Norethindrone can be decreased when it is combined with Topiramate.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Topiramate.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Topiramate.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Topiramate.
OrlistatThe serum concentration of Topiramate can be decreased when it is combined with Orlistat.
OrphenadrineTopiramate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Topiramate.
ParaldehydeTopiramate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Topiramate is combined with Paroxetine.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Topiramate.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Topiramate.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Topiramate.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Topiramate.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Topiramate.
PramipexoleTopiramate may increase the sedative activities of Pramipexole.
PrimidoneThe risk or severity of adverse effects can be increased when Topiramate is combined with Primidone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Topiramate.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Topiramate.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Topiramate.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Topiramate.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Topiramate.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Topiramate.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Topiramate.
QuinidineTopiramate may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Topiramate.
RopiniroleTopiramate may increase the sedative activities of Ropinirole.
RotigotineTopiramate may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Topiramate.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Topiramate.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Topiramate.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Topiramate.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Topiramate.
SuvorexantTopiramate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
ThalidomideTopiramate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Topiramate.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Topiramate.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Topiramate.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Topiramate.
TorasemideTorasemide may increase the hypokalemic activities of Topiramate.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Topiramate.
TrichlormethiazideTrichlormethiazide may increase the hypokalemic activities of Topiramate.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Topiramate.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Topiramate.
TrimethobenzamideThe risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Topiramate.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Topiramate.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Topiramate.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Topiramate.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Topiramate.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Topiramate.
Valproic AcidThe risk or severity of adverse effects can be increased when Topiramate is combined with Valproic Acid.
ZolpidemTopiramate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Topiramate.
Food Interactions
  • Following a single dose of the extended-release formulation with a high fat meal, Cmax of topiramate increased by 37% and shortened the Tmax to approximately 8 hours. AUC was not effected. According to the FDA label, Trokendi XR can be taken without regard to food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Nowakowska E, Kus K, Czubak A, Jedrzejewska J: Memory improving and antidepressant effects of topiramate in rats. Arzneimittelforschung. 2009;59(10):487-92. doi: 10.1055/s-0031-1296431. [PubMed:19998575 ]
  4. Braga MF, Aroniadou-Anderjaska V, Li H, Rogawski MA: Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons. J Pharmacol Exp Ther. 2009 Aug;330(2):558-66. doi: 10.1124/jpet.109.153908. Epub 2009 May 5. [PubMed:19417176 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient.
Gene Name:
SCN1A
Uniprot ID:
P35498
Molecular Weight:
228969.49 Da
References
  1. Coppola G, Capovilla G, Montagnini A, Romeo A, Spano M, Tortorella G, Veggiotti P, Viri M, Pascotto A: Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res. 2002 Mar;49(1):45-8. [PubMed:11948006 ]
  2. Ceulemans B, Cras P: "Severe myoclonic epilepsy in infancy". Relevance for the clinician of severe epilepsy starting in infancy. Acta Neurol Belg. 2004 Sep;104(3):95-9. [PubMed:15508261 ]
  3. Ceulemans B, Boel M, Claes L, Dom L, Willekens H, Thiry P, Lagae L: Severe myoclonic epilepsy in infancy: toward an optimal treatment. J Child Neurol. 2004 Jul;19(7):516-21. [PubMed:15526956 ]
  4. Korff C, Laux L, Kelley K, Goldstein J, Koh S, Nordli D Jr: Dravet syndrome (severe myoclonic epilepsy in infancy): a retrospective study of 16 patients. J Child Neurol. 2007 Feb;22(2):185-94. [PubMed:17621480 ]
  5. Nieto Barrera M, Candau Fernandez Mensaque R, Nieto Jimenez M: [Severe myoclonic epilepsy in infancy (Dravet's syndrome). Its nosological characteristics and therapeutic aspects]. Rev Neurol. 2003 Jul 1-15;37(1):64-8. [PubMed:12861512 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Voltage-gated cation channel activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK1
Uniprot ID:
P39086
Molecular Weight:
103979.665 Da
References
  1. Rogawski MA, Gryder D, Castaneda D, Yonekawa W, Banks MK, Lia H: GluR5 kainate receptors, seizures, and the amygdala. Ann N Y Acad Sci. 2003 Apr;985:150-62. [PubMed:12724156 ]
  2. Gryder DS, Rogawski MA: Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci. 2003 Aug 6;23(18):7069-74. [PubMed:12904467 ]
  3. Kaminski RM, Banerjee M, Rogawski MA: Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology. 2004 Jun;46(8):1097-104. [PubMed:15111016 ]
  4. Braga MF, Aroniadou-Anderjaska V, Li H, Rogawski MA: Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons. J Pharmacol Exp Ther. 2009 Aug;330(2):558-66. doi: 10.1124/jpet.109.153908. Epub 2009 May 5. [PubMed:19417176 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Maryanoff BE, McComsey DF, Costanzo MJ, Hochman C, Smith-Swintosky V, Shank RP: Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform. J Med Chem. 2005 Mar 24;48(6):1941-7. [PubMed:15771438 ]
  2. Ma L, Huang YG, Deng YC, Tian JY, Rao ZR, Che HL, Zhang HF, Zhao G: Topiramate reduced sweat secretion and aquaporin-5 expression in sweat glands of mice. Life Sci. 2007 Jun 6;80(26):2461-8. Epub 2007 Apr 29. [PubMed:17521680 ]
  3. Di Fiore A, Scozzafava A, Winum JY, Montero JL, Pedone C, Supuran CT, De Simone G: Carbonic anhydrase inhibitors: binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1726-31. Epub 2007 Jan 8. [PubMed:17251017 ]
  4. Casini A, Antel J, Abbate F, Scozzafava A, David S, Waldeck H, Schafer S, Supuran CT: Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett. 2003 Mar 10;13(5):841-5. [PubMed:12617904 ]
  5. Winum JY, Scozzafava A, Montero JL, Supuran CT: Sulfamates and their therapeutic potential. Med Res Rev. 2005 Mar;25(2):186-228. [PubMed:15478125 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
Gene Name:
CA4
Uniprot ID:
P22748
Molecular Weight:
35032.075 Da
References
  1. Abbate F, Casini A, Owa T, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23. [PubMed:14684331 ]
  2. Dodgson SJ, Shank RP, Maryanoff BE: Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia. 2000;41 Suppl 1:S35-9. [PubMed:10768298 ]
  3. Masereel B, Rolin S, Abbate F, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem. 2002 Jan 17;45(2):312-20. [PubMed:11784136 ]
  4. Vullo D, Franchi M, Gallori E, Antel J, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J Med Chem. 2004 Feb 26;47(5):1272-9. [PubMed:14971907 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 24, 2016 03:05